TB & Biologics
Testing for TB is critical prior to biologic therapyTreatment with biologic agents, in particular tumor necrosis factor-alpha (TNF-α) inhibitors, has revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. However, patients receiving anti-TNF-α therapy are at increased risk of tuberculosis (TB) infection. To reduce this risk, the WHO recommends latent TB infection (LTBI) testing in patients starting biologics (1).
LTBI management and biologicsJoin Dr. Nikolayevskyy for a live webinar to learn about latent TB infection screening before biologics.
Screening for TB before biologicsLearn more about potential benefits of testing with QuantiFERON technology prior to TNF-α inhibitor therapy.
Before you initiate TNF-α inhibitor therapy, trust QFT-Plus for accurate TB detection
For more information, contact your QIAGEN sales representative.